

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

UEHARA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/006865

FILED: 24 JUNE 2004

U.S. APPLICATION NO: 10/560,940

35 USC §371 DATE: 15 DECEMBER 2005

FOR: TABLET COMPRISING FLUVASTATIN AND CARMELLOSE  
CALCIUM**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed February 16, 2007. Since it is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

A Copy of this reference and the English Equivalent are enclosed herewith.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PC/4-33240A  
APPLICATION NO.  
10/550,540  
APPLICANT  
UEHARA ET AL.  
FILING DATE  
DECEMBER 15, 2005

40560940 - GAU: 1615

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Shokuhin Tenkabusu Handbook, Maruzen KK, p. 71-76, (1989), JP-A-10-226644 and English Equivalents thereof.
	AS	
	AT	

EXAMINER /Hasan Ahmed/

DATE CONSIDERED 01/23/2010


\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /HA/

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7877

  
John W. Kung  
Attorney for Applicants  
Reg. No. 44,199

Date: 3/5/87